Articles On Adalta (ASX:1AD)

ASX has gained to cinch seventh straight session in the green 10 of 11 sectors on the up Bank index lifts 1.6pc as CBA hits record new share price high The ASX is on trajectory to return to pre-trade war highs after lifting for a seventh...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10:15, once trading kicks off in earnes...

ASX recovers from early dip to post 0.24pc gain Tech stocks surge with sector up 4pc Energy and Materials weigh on gains, down more than 1pc each An after-hours surge in US tech stocks has lit the Aussie tech sector on fire, rocketing up...

AdAlta (ASX:1AD) has announced aims to raise up to $1.3 million in a renounceable rights issue to advance its East to West cellular immunotherapy strategy.  Eligible shareholders can apply for two new shares for every three held at $0.03 pe...

Energy and Tech sectors up about 1.5pc each Technology index boosted 1.26pc Materials the only laggard, down 0.59pc While a late run of bears has taken some of the wind out of the ASX’s sails, the Aussie market is firmly in the green toda...

AdAlta subsidiary AdCella brings cutting-edge cellular immunotherapies from Asia – particularly China – into Western markets AdCella has backing of SYNthesis BioVentures Fund, which invests in therapeutics development The biotech fund beli...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim chats with AdAlta (ASX:1AD) CEO and managing director Dr Tim Oldham. For several years, AdAlta...

Australia’s S&P/ASX 200 records its first back-to-back monthly fall since October 2023, down 3.39% in March Ten out 11 S&P/ASX 200 sectors posted losses with utilities the only sector in the black, up 1.52% Metal Powder Works rises...

ASX rebounds 1pc with tech and real estate leading the way Nanosonics jumps  after FDA gives approval Aussie job numbers dip, fuelling rate cut hopes   The ASX had a cracker of a session on Thursday, up by 1.2% as it registered the best o...

AdAlta (ASX:1AD) has built on a deal with SYNthesis BioVentures Fund One, which plans to invest $500,000 in seed funding for its subsidiary AdCella, with a total commitment of up to $2 million. It means AdCella now won’t rely on further cap...

ASX rises on global optimism and China boost Energy and miners shine, Mineral Resources jumps after upgrade Copper hits five-month high, gold edges up   The ASX kicked off the week with a 0.75% bump as global sentiment surged. Today’s reb...

Highlights Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options. AdAlta, Cynata, and Amplia are advancing innovative therapeutic approaches. Australian biotechnology companies are expanding...

Idiopathic pulmonary fibrosis is a life-threatening lung disease AdAlta’s lead candidate AD-214 is a first-in-class molecule designed to treat IPF Amplia and Cynata therapies also show promise in treating the disease, which has limited tre...

ASX dips as traders weigh China’s stimulus against Trump’s tariffs Miners soften blow but insurance stocks still taking hits Trump gives speech to Congress, here’s what he said…   The ASX had a bit of a ride on Wednesday, with a sharp dip...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Stockhead’s Fraser Palamara chats withAdAlta (ASX:1AD) managing director Tim Oldham to get the short end of the long story on the company’s latest news. The company announced it’s prioritising its East to West strategy in a bid to to gain a...

AdAlta prioritising East to West cellular immunotherapy strategy  Company now has three products in exclusive due diligence after executing two non-binding term sheets Strategy expected to allow for value realisation in relatively short ti...

AdAlta (ASX:1AD) has unveiled a new grand plan to take cell therapy candidates from Southeast Asia, firm them up in Australian early-stage tests, and then licence those products if successful to European and American markets. But shareho...

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

ASX 200 lifts on tech rally, miners struggle Barrick Gold threatens Mali shutdown over shipping restrictions Bitcoin bounces back after recent slump   The ASX 200 index crept up 0.34% on Tuesday, thanks to a rally in tech following the Na...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

What is idiopathic pulmonary fibrosis (IPF)? What’s it like living with it? And what treatments are currently available? AdAlta (ASX:1AD) managing director and CEO Dr Tim Oldham joins the Stockhead TV studio to investigate these questions a...

ASX up as mining gains offset tech and bank losses Silex, Paladin and uranium stocks soar on supply squeeze Goldman cuts Aussie GDP forecast as US tariffs loom   After a soft start to the day, the ASX bounced back and closed the day 0.3% ...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

AdAlta boosts leadership of subsidiaries with appointments of two consultant chief medical officers AdCella’s Kevin Lynch will support selection of in-licensed cellular immunotherapies and the design and execution of Phase 1 clinical trial...

ASX edges slightly up by 0.12pc as traders rethink rate cuts Consumer staples shine while gold miners gain amid global tensions 29Metals plunges after cash reserve drop and production decline   The ASX ticked up higher by 0.1% on Wednesd...

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto...

Stockhead’s Sarah Hughan sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news. The company’s formed a clinical advisory board to support the development of...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on AdAlta (ASX:1AD) recruiting a team of world leaders in idiopathic pulmonary fibrosis to form a company cli...

AdAlta forms a clinical advisory board to advance its lead i-body enabled drug candidate AD-214 Board members are renowned experts in pulmonary medicine and fibrosis AdAlta has also engaged a specialist adviser for Idiopathic Pulmonary Fib...

  ASX 200 index falls despite gains in energy stocks Smaller oil and gas firms benefit from rising crude prices Iron ore stocks drop as prices retreat   The ASX 200 index fell hard on Friday, down by 0.75%, despite some gains in the Ener...

  To register for today's webinar click here. Platina Resources Limited (ASX:PGM) has confirmed two gold intersections at its Challa Gold Project in Western Australia, including 12m at 0.66g/t Au from aircore hole CHAC0155. The findings sug...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Coles Group Ltd (ASX: COL) shares have enjoyed a strong run in 2024. They are up 18.7% this year to date and finished trading on Tuesday at $19.12 apiece. With the S&P/ASX 200 Index (ASX: XJO) 7.2% higher in the same period, Coles sh...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

The ASX ended higher after a slow start Energy stocks leading while telcos and miners lagged Asian stocks mostly declined amid ongoing economic weakness    After a sluggish start, the ASX ended Monday higher by 0.22% as September trading...

Local markets opened lower this morning, with the decline slightly exceeding expectations. Despite a decent performance on Wall Street overnight, which might have suggested a more positive start for the ASX, the Australian share market face...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode Tim chats with Tim Oldham, CEO and managing director at AdAlta (ASX:1AD). The biotech company is devo...

  Tim Oldham – CEO & Managing Director – AdAlta Limited (ASX:1AD) is a clinical-stage biotechnology company. The company’s lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis.

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX rises on Monday after Wall Street banked a belter on Friday All 11 local sectors higher, InfoTech winning the race for Best in Show Aruma Resources led the small caps winners   The local benchmark moved strongly into positive terri...

AdAlta entered collaboration with SYNthesis BioVentures Fund to establish AdCella during Q4 FY24 Cell Therapies chosen as preferred manufacturing partner for AdCella’s cellular immunotherapies Institutional investment, reduced expenditure...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

ASX starts June positively, extending May gains  Property prices in Australia rose by 0.8% in May, with Sydney remaining the most expensive city Lovisa plunges by -10% as John Cheston takes over as CEO   The ASX has started the month of...

1AD raises $1.9 million of new equity from the exercise of listed 1ADOA options, led by an existing major shareholder Options exercised at a 20% premium to the closing price on May 29 2024 Proceeds from exercised options to help AdAlta adv...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead’s Sarah Hughan sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news. The Aussie biotech has chosen Cell Therapies as its preferred manufacturer fo...